Mode
Text Size
Log in / Sign up
Phase 4 N=48 Randomized Treatment

Efficacy of Opioid-limiting Pain Management Protocol in Men Undergoing Urethroplasty

Pain, Postoperative · Urethral Stricture

Enrolled (actual)
48
Serious AEs
0.0%
Results posted
Sep 2024
Primary outcome: Primary: Participant Pain Control: Numerical Rating Scale (NRS) — 1.2; .625 score on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Oxycodone (Drug); Acetaminophen (Drug); Gabapentin (Drug); celebrex (Drug); Bupivacaine (Drug); Ibuprofen 800 mg (Drug); Dexamethasone (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Male
Sponsor
University of Alabama at Birmingham
Primary completion
Apr 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Participant Pain Control: Numerical Rating Scale (NRS)
1.2; .625
PRIMARY
Opioid Medication Use
5.14; 4.96

Summary

The investigator's study aims to see if an enhanced recovery regimen of pain medications before and during surgery will decrease the use and risk of opioid pain medications as well as improve pain control in anterior urethroplasty patients. Participants will be randomized to one of two pain regimens (enhanced recovery regimen vs standard regimen).

Eligibility Criteria

Inclusion Criteria

  • Men greater than 18 years of age who are scheduled for anterior urethroplasty surgery

Exclusion Criteria

  • Any patient not classified as a II or III on the American Society of Anesthesiologists (ASA) physical status classification system.
  • General anesthesia or neuraxial anesthesia with epidural used as anesthetic techniques
  • Allergy/intolerance to local anesthetic or steroids
  • Pre-existing neurological and/or anatomical deficit that would preclude regional block
  • Coexisting coagulopathy such as hemophilia or von Willebrand Disease
  • BMI greater than 40 or less then 20
  • History of intravenous drug or opioid abuse
  • History of opioid use within a week prior to urethroplasty
  • History of any chronic pain syndrome
  • Posterior urethroplasty
  • Patients with chronic kidney disease
  • Patients allergic to NSAIDs
  • Patients requiring more than one buccal graft harvest
  • Patients with graft urethroplasty with site other than buccal
  • Patients with a history of previous urethroplasty
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03859024). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search